This transcript has been edited for clarity.
This is Mark Lewis, MD, director of gastrointestinal (GI) oncology at Intermountain Healthcare in Salt Lake City, Utah. I want to summarize some takeaway points from the 2022 American Society of Clinical Oncology (ASCO) GI Cancers Symposium.
Many oncologists will tell you that the litmus test of a successful conference is how much it affects your practice, and I believe that data were presented at this meeting that will certainly affect practice immediately and give us a sneak preview of how our treatments may change in the future.